VVOS
Vivos Therapeutics, Inc.Company Information
- Company Name
- Vivos Therapeutics, Inc.
- CIK
- CIK0001716166
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- VVOS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 3841
- SIC Description
- Surgical & Medical Instruments & Apparatus
- Ticker
- VVOS
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-03-31
- Last sale
- —
- Shares purchased (TTM)
- 1,353,625
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 531,027
- Shares outstanding
- 17,681,945
- Ownership
- 3.00%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -45.77%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents At Carrying Value | 2 | 2 | 2 | 3 | 4 | 2 | 6 | 6 | 7 | 3 | 2 | 1 | ||||||
| Accounts Receivable Net Current | 1 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 4 | 5 | 4 | 6 | 7 | 4 | 7 | 7 | 8 | 4 | 2 | 2 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Goodwill | 9 | 9 | 9 | 8 | 8 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Property Plant And Equipment Net | 4 | 4 | 4 | 6 | 5 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Operating Lease Right Of Use Asset | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Intangible Assets Net Excluding Goodwill | 4 | 4 | 4 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deposits Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 24 | 25 | 25 | 26 | 26 | 11 | 15 | 15 | 16 | 12 | 11 | 10 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | ||||||
| Accrued Liabilities Current | 7 | 6 | 6 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Contract With Customer Liability Current | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 20 | 18 | 18 | 7 | 6 | 5 | 5 | 5 | 7 | 8 | 7 | 7 | ||||||
| Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | ||||||
| Long Term Debt Current | 8 | 7 | 8 | 0 | 0 | - | - | - | - | - | - | - | ||||||
| Other Liabilities Current | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Contract With Customer Liability Noncurrent | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 3 | 4 | 4 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | ||||||
| Finance Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | ||||||
| Long Term Debt Noncurrent | 0 | 0 | 0 | 8 | 8 | - | - | - | - | - | - | - | ||||||
| Other Liabilities Noncurrent | 1 | 1 | 1 | 1 | 1 | - | - | - | - | - | - | - | ||||||
| Liabilities | 28 | 26 | 27 | 23 | 21 | 7 | 7 | 8 | 9 | 11 | 10 | 10 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital | 134 | 132 | 124 | 121 | 118 | 112 | 112 | 109 | 105 | 97 | 93 | 89 | ||||||
| Stockholders Equity | -4 | -1 | -2 | 3 | 5 | 4 | 8 | 8 | 6 | 1 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -139 | -133 | -125 | -118 | -113 | -108 | -104 | -101 | -99 | -97 | -93 | -89 | ||||||
| Minority Interest | -0 | 0 | 0 | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities And Stockholders Equity | 24 | 25 | 25 | 26 | 26 | 11 | 15 | 15 | 16 | 12 | 11 | 10 | ||||||
| Allowance For Doubtful Accounts Receivable | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | ||||||
| Preferred Stock Shares Issued | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 15 | 13 | 9 | 8 | 7 | 6 | 6 | 5 | 3 | 3 | 2 | 1 | ||||||
| Shares Outstanding | 15 | 13 | 9 | 8 | 7 | 6 | 6 | 5 | 3 | 3 | 2 | 1 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialVivos Therapeutics, Inc. (VVOS) — SEC Financial Statements & Analysis
Vivos Therapeutics, Inc. (VVOS) is a surgical & medical instruments & apparatus company, incorporated in DE. Vivos Therapeutics, Inc. trades on Nasdaq as: VVOS. Vivos Therapeutics, Inc. (VVOS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Vivos Therapeutics, Inc. carries a market cap of $8.05M, a P/E ratio of -0.32x, a P/B ratio of -2.02x, a P/S ratio of 0.38x, an enterprise value of $14.47M, and an EV/EBITDA multiple of -0.70x. On profitability, it posts a gross margin of 61.89%, an operating margin of -107.89%, a net margin of -122.08%, a Return on Equity (ROE) of -8548.07%, a Return on Assets (ROA) of -101.70%, and a Return on Invested Capital (ROIC) of -399.38%. Per share, it reports EPS of $-1.44, diluted EPS of $-1.44, free cash flow per share of $-1.08, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 45.21% year-over-year, net income growth of 78.18% year-over-year, and EPS growth of -8.43% year-over-year. On the balance sheet, it maintains a current ratio of 0.21x, a quick ratio of 0.16x, working capital of $-16.18M, a debt-to-equity ratio of -7.06x, a debt ratio of 1.17, an interest coverage ratio of -225.91x, free cash flow of $-19.18M (TTM), and net debt of $6.42M. Figures sourced from SEC EDGAR.
- Market Cap
- $8.05M
- P/E TTM
- -0.32x
- EPS TTM
- $-1.44
- P/B TTM
- -2.02x
- ROE TTM
- -8548.07%
- ROA TTM
- -101.70%
- Debt To Equity
- -7.06x
- Free Cash Flow TTM
- $-19.18M
- Net Revenue TTM Growth 1Y
- 45.21%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Vivos Therapeutics, Inc. in?
Vivos Therapeutics, Inc. (VVOS) operates in the Surgical & Medical Instruments & Apparatus industry.
What exchange does VVOS trade on?
Vivos Therapeutics, Inc. (VVOS) trades on the Nasdaq.
Where is Vivos Therapeutics, Inc. incorporated?
Vivos Therapeutics, Inc. is incorporated in DE.
When was Vivos Therapeutics, Inc. (VVOS)'s most recent SEC filing?
Vivos Therapeutics, Inc. (VVOS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is VVOS's market cap?
Vivos Therapeutics, Inc. (VVOS) has a market capitalization of $8.05M as of 2026-06-30.
What is VVOS's EPS (earnings per share)?
Vivos Therapeutics, Inc. (VVOS)'s trailing twelve month EPS is $-1.44 as of 2026-06-30.
What is VVOS's ROE (return on equity)?
Vivos Therapeutics, Inc. (VVOS)'s trailing twelve month Return on Equity (ROE) is -8548.07% as of 2026-06-30.
What is VVOS's ROA (return on assets)?
Vivos Therapeutics, Inc. (VVOS)'s trailing twelve month Return on Assets (ROA) is -101.70% as of 2026-06-30.
What is VVOS's ROIC (return on invested capital)?
Vivos Therapeutics, Inc. (VVOS)'s trailing twelve month Return on Invested Capital (ROIC) is -399.38% as of 2026-06-30.
What is VVOS's EV/EBITDA?
Vivos Therapeutics, Inc. (VVOS)'s trailing twelve month EV/EBITDA is -0.70x as of 2026-06-30.